HSE has ‘almost exhausted’ its 2019 funding for new drugs

HSE has ‘almost exhausted’ its 2019 funding for new drugs

Professor Michael Barry, who heads up the National Centre for Pharmacoeconomics (NCPE), was speaking after the HSE informed Biogen, manufacturer of Spinraza, it would not fund the drug

The HSE has “almost exhausted” the available funding it has for new drugs in 2019 just two months into the year, the state’s medicines watchdog has warned.

Professor Michael Barry, who heads up the National Centre for Pharmacoeconomics (NCPE), was speaking after the HSE informed Biogen, manufacturer of Spinraza, it would not fund the drug.

Barry’s comments will set off alarm bells amid the pharma sector, which has criticised the delays that it claims Irish...

Subscribe from just 1€

Exclusive offers

Choose the subscription that is right for you

Monthly Subscription

€1

For the first month

€19.99 Monthly Thereafter

Subscribe today

Cancel anytime

Annual Subscription

€200€149

For the first year

€199.99 annually thereafter

Subscribe today

Cancel anytime

Quarterly Subscription

€55€42

For the first 90 days

€55.00 quarterly Thereafter

Subscribe today

Cancel anytime

These offers are not available for current subscribers. Offers and pricing are subject to change without notice.

Terms & Conditions Apply

Please Subscribe or Log in to continue

Subscribe Login

Related Articles

More from The Business Post